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Background: Huntington’s disease (HD) is a fatal progressive neurodegenerative disorder caused by the expansion
of the polyglutamine repeat region in the huntingtin gene. Although the disease is triggered by the mutation of a
single gene, intensive research has linked numerous other genes to its pathogenesis. To obtain a systematic
overview of these genes, which may serve as therapeutic targets, CHDI Foundation has recently established the HD
Research Crossroads database. With currently over 800 cataloged genes, this web-based resource constitutes the
most extensive curation of genes relevant to HD. It provides us with an unprecedented opportunity to survey
molecular mechanisms involved in HD in a holistic manner.
Methods: To gain a synoptic view of therapeutic targets for HD, we have carried out a variety of bioinformatical
and statistical analyses to scrutinize the functional association of genes curated in the HD Research Crossroads
database. In particular, enrichment analyses were performed with respect to Gene Ontology categories, KEGG
signaling pathways, and Pfam protein families. For selected processes, we also analyzed differential expression,
using published microarray data. Additionally, we generated a candidate set of novel genetic modifiers of HD by
combining information from the HD Research Crossroads database with previous genome-wide linkage studies.
Results: Our analyses led to a comprehensive identification of molecular mechanisms associated with HD.
Remarkably, we not only recovered processes and pathways, which have frequently been linked to HD (such as
cytotoxicity, apoptosis, and calcium signaling), but also found strong indications for other potentially disease-relevant
mechanisms that have been less intensively studied in the context of HD (such as the cell cycle and RNA splicing, as
well as Wnt and ErbB signaling). For follow-up studies, we provide a regularly updated compendium of molecular
mechanism, that are associated with HD, at http://hdtt.sysbiolab.eu. Additionally, we derived a candidate set of 24
novel genetic modifiers, including histone deacetylase 3 (HDAC3), metabotropic glutamate receptor 1 (GRM1), CDK5
regulatory subunit 2 (CDK5R2), and coactivator 1ß of the peroxisome proliferator-activated receptor gamma
(PPARGC1B).
Conclusions: The results of our study give us an intriguing picture of the molecular complexity of HD. Our analyses
can be seen as a first step towards a comprehensive list of biological processes, molecular functions, and
pathways involved in HD, and may provide a basis for the development of more holistic disease models and
new therapeutics.* Correspondence: mfutschik@ualg.pt
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Huntington disease (HD) is an autosomal-dominant
neurodegenerative disorder characterized by severe im-
pediment in movement, decline in cognitive functions,
as well as behavioral abnormalities. In most cases, the
first symptoms of HD are observed in patients between
the ages of 35 and 50. The average life expectancy after
disease onset is around 20 years. So far, no cure has been
found for HD, and its treatment remains symptomatic.
The prevalence of HD is highest for people with
Caucasian descent with an estimated 40–100 cases per
million. Notably, HD displays a distinct neuropathology:
the disease primarily affects GABAergic medium spiny
striatal neurons, leading to cell loss and atrophy of the
caudate nucleus and putamen in the basal ganglia. Al-
though the most prominent neuronal cell death is
observed in the basal ganglia, other brain regions may
show damage as well [1,2]. HD is caused by CAG repeat
expansion in exon 1 of the huntingtin gene (identified in
1993 at chromosomal location 4p16 and originally
termed IT15), which results in a long stretch of polyglu-
tamine close to the amino-terminus of the Huntingtin
protein (Htt) [3]. Remarkably, the length of the polyglu-
tamine tract in the mutant Htt explains 40-50% of the
variance in the age of onset, with longer repeats leading
to earlier onset [4-8]. Although the exact mechanisms
are yet to be understood, it is believed that HD results
from both a gain-of-function of the mutant protein, as
well as a loss-of-function of the wild-type protein [9].
Wild-type Htt is a large protein, over 3000 amino acids
long, and is expressed ubiquitously throughout the body.
Its sequence exhibits several consensus sites for protein
interaction and modification, but it has no close homo-
log among human proteins based on its full sequence.
Although wild-type Htt has been associated with several
cellular processes, such as transcriptional regulation,
vesicular transport and apoptosis; its exact function is
not yet clear [10]. A distinct hallmark of HD is the ap-
pearance of cellular inclusion bodies due to the aggrega-
tion of mutant Htt.
Even though HD is caused by a mutation in a single
gene, numerous additional genes may play a role in HD.
Indeed, the observed variability in the pathogenesis, i.e.
onset, severity and progression of HD, strongly indicates
that other modifying environmental and genetic factors
exist, apart from the disease causing poly-Q expansion
in mutant Htt [3,11]. In particular, age of onset and dis-
ease symptoms can differ considerably between HD
patients despite similar glutamine repeat length. More-
over, the residual variance in age of onset, i.e. the vari-
ance after adjusting for the differences in poly-Q length,
shows a high degree of heritability [11]. These observa-
tions have evoked an intense search for genetic modi-
fiers. As a result, several linkage studies have indicatedthat polymorphisms in other genes - apart from Htt -
may modify onset and course of HD [12]. Furthermore,
the use of RNAi screening in lower model organisms
revealed that altering the expression of a surprisingly
large number of genes can influence the aggregation of
mutant Htt [13,14].
To systematically catalog the various potential genetic
modifiers, as well as other genes influencing HD patho-
genesis, CHDI Foundation has established a database
termed HD Research Crossroads (or in short, HD Cross-
roads). This gene-centric resource currently summarizes
information and validated data for over 800 genes rele-
vant to HD pathogenesis. It provides links to supporting
studies and presents the collected evidence of the role of
these genes in HD. Thus, it enables the user to critically
assess the classification of individual genes in HD Cross-
roads and thus their relevance to HD. (We will hence-
forth refer to the set of curated genes in HD Crossroads
collectively as “HD-relevant” genes, although the
amount of evidence for individual genes can be very dif-
ferent). Furthermore, HD Crossroads includes several
scoring schemes for genes with respect to their potential
as drug targets and allows registered users to add com-
ments regarding particular genes. Its primary aim is to
support the process of prioritizing gene targets for thera-
peutic intervention.
Apart from the gene-centric focus, the collected infor-
mation provides a unique possibility for more holistic
bioinformatical and statistical analyses. Since HD Cross-
roads comprises the largest and most comprehensive
collection of curated HD-relevant genes to date, it can
serve as a basis to obtain an overview of the biological
mechanisms underlying HD. Such an assessment is not
only important for HD research, but may be beneficial
for the study of related diseases. Notably, HD is the most
prominent example of the family of trinucleotide repeat
disorders (including spinocerebellar ataxias 1, 2, 3, 6, 7,
17, spinobulbar muscular atrophy and dentatorubropalli-
doluysian atrophy), which share disease-related mechan-
isms despite their distinct phenotypes [15]. Thus, new
insights into HD might give us a new rationale for the
study of neurodegeneration in general.
Seeking a broader understanding of the molecular
manifestation of HD, we utilized the curated set of HD-
relevant genes and carried out extensive bioinformatical
and statistical analyses. We translated the set of genes
into a functional profile, exploiting annotation from sev-
eral public databases. Our aim was to obtain a synoptic
view of molecular processes and pathways that are
enriched in HD-relevant genes. With these analyses, we
have generated a compendium of molecular mechanisms
that might play critical roles in HD. The compendium
links biological processes, molecular functions and path-
ways to sets of HD-relevant genes and provides the
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tential follow-up studies. Additionally, we have derived a
list of candidates for genetic modifiers by integrating
results from previous genome-wide linkage studies.
We would like to emphasize that this work is not
intended as a review of the molecular pathogenesis
underlying HD, although we will discuss our results
with respect to numerous earlier findings. For a more
exhaustive presentation of the current understanding
of HD, the reader is referred to dedicated recent reviews
[9,16,17].
Methods
HD Research crossroads database
The HD Research Crossroads database can be accessed
at http://www.hdresearchcrossroads.org/. On user regis-
tration, the full list of curated genes can be downloaded
from HD Crossroads. The genes included in the data-
base are evaluated based on a variety of parameters such
as Target Validation Score, Drugability Score, desired
pharmacology, mechanistic class and target class. These
parameters provide assistance in prioritizing target genes
for pharmacological intervention. Notably, the collection
of information and the inclusion of genes as targets is an
on-going process, i.e., the HD Research Crossroads data-
base is constantly being updated with the latest findings.
The most important parameter for our study is the
Target Validation Score (TVS). The TVS of a gene cap-
tures the status of experimental validation of disease-
modifying effects; it ranges from 0.0 to 5.0 (with 0.0
being lowest and 5.0 being highest). The scheme for
assigning a TVS is as follows: a score of 5.0 is assigned
to genes if a drug or a gene therapy modulating the gene
has demonstrated efficacy in a Phase 3 clinical trial. A
score of 4.5 is assigned to genes if a Phase 2 clinical trial
of a drug or gene therapy had a positive outcome, or the
HD phenotype in a non-rodent large animal mammalian
model for HD (e.g. primate or sheep) is improved upon
manipulation of the gene. A score of 4.0 signifies that an
improvement of the HD phenotype in rodent models
was observed using a therapeutically relevant drug or
genetic intervention that is highly specific for this gene.
A score of 3.5 is assigned when the gene is associated
with HD in a linkage study in humans, or when the ma-
nipulation of the gene leads to changes in the HD
phenotype in rodent models. A score of 3.0 is assigned
to cases where a causal relationship with HD was
observed in an in vitro cell culture or lower organism
model of HD upon genetic or pharmacologic modifica-
tion. A score of 2.5 is assigned to genes that show an
altered pathway or functional activity in HD. A score of
2.0 is assigned if a gene shows a change in expression or
cellular distribution in HD, or if the corresponding pro-
tein binds to mutant Htt. A score of 1.0 is assigned togenes present and active in HD-relevant brain regions or
linked to a HD-relevant biological mechanism. Finally, a
score of 0.0 is recorded for genes implicated in neurode-
generation or polyglutamine dysfunction based on
genome-wide screens. Our analyses were carried out on
the list of HD-relevant genes downloaded on 3rd of
January 2011.
Functional enrichment analysis
All statistical analyses were performed in the R/Biocon-
ductor environment (http://www.bioconductor.org; Bio-
base version 2.6.1) using several annotation packages.
Different types of statistical investigations were con-
ducted using different publically available resources.
First, we carried out Gene Ontology (GO) based ana-
lyses. GO represents a structured, hierarchical system,
which associates a gene product with a defined set of
molecular functions, biological processes and cellular
components. Currently, GO includes annotations for
over 17,500 human gene products. In addition to the full
set of GO categories, a reduced set of GO categories was
utilized. It was created by the GO Consortium and is re-
ferred to as generic GO Slim. It includes only 127 cat-
egories (a subset of the 8245 categories of the full GO
ontology) and can be downloaded from the GO website
(http://www.geneontology.org/).
Our second analysis aimed to identify canonical path-
ways enriched in HD-relevant genes. For this purpose,
we utilized information from the KEGG pathway data-
base (http://www.genome.jp/kegg/pathway.html), which
provides a large collection of manually derived schemes
of metabolic and signaling pathways, as well as of a var-
iety of diseases and other processes. The KEGG database
employed in our analysis comprises over 5,000 human
protein genes mapped to 220 pathways. Additionally, in-
formation from the Pfam database was used in order to
examine whether specific protein families are over-
represented in the set of HD-relevant genes. The Pfam
database (http://pfam.sanger.ac.uk) is a collection of
conserved protein families determined by multiple align-
ments and profiling through statistical models. Informa-
tion from GO, KEGG and PFAM was obtained through
their corresponding Bioconductor annotation packages,
i.e., GO.db (version 2.3.5), KEGG.db (version 2.3.5) and
PFAM.db (version 2.3.5).
Enrichment of HD-relevant genes in GO categories,
KEGG pathways and Pfam protein families was tested
using the Fisher's exact test. As reference set, the anno-
tated human genome was used. Subsequently, statistical
significance was adjusted for multiple testing, applying the
Benjamini and Hochberg procedure [18]. The final signifi-
cance for enrichment is given as False Discovery Rates
(FDRs). The complete set of GO categories, KEGG path-
ways and Pfam protein families with their corresponding
Figure 1 Distribution of TVS. The pie-chart shows the distribution
of the Target Validation Score (TVS) in HD Crossroads. The numbers
of genes with specific scores also are displayed.
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Since HD Crossroads is constantly expanding, we will to
regularly repeat the enrichment analyses of HD-relevant
genes and to provide these results on our webpage (http://
hdtt.sysbiolab.eu/).
Gene expression analysis
For gene expression analysis, microarray data for the
human HD caudate nucleus and different HD mouse
models (R6/2; BDNF-KO; CHL2; striatal cell line)
were utilized [19-22]. Expression data were obtained
from Gene Expression Omnibus database (GSE3790,
GSE10263, GSE3583) and pre-processed using RMA
(Robust Multi-array Average) as implemented in the R/
Bioconductor environment [23]. The Bioconductor
limma package was used to detect differential expression
in HD compared with their corresponding controls. An
adjusted p-value of 0.01 was selected as the threshold
for significance. Additionally, a minimum absolute fold
change of 1.2 was required for differential expression.
Subsequently, the enrichment of the GO cell cycle and
RNA splicing categories, as well as KEGG ErbB and
Wnt pathways, by differentially expressed genes was cal-
culated using Fisher's exact test. For promoter analysis,
the Expander software with default settings was employed.
Chromosomal mapping
The chromosomal location of genes was obtained
from the Ensmart server (http://www.ensembl.org/Multi/
martview). As loci modifying age of onset, we used those
that were reported in the genome-wide scans by Li et al.
(HD MAPS study) and by Gayán et al. [24,25]. The LOD
score (logarithm (base 10) of odds) for suggestive evidence
for linkage were retrieved from the publications. In the
case of the HD MAPS study, the modifier loci and corre-
sponding maximum LOD scores were given as 2q33
(LOD: 1.63), 4p16 (1.93), 5q31-32 (2.02), 6p22 (2.29),
6q23-24 (2.28) and 18q22 (1.74). In the case of the study
by Gayán et al., the reported loci were 2p25 (4.29), 2q35
(3.39), 4p16 (1.49), 4p21 (2.07), 5p14 (3.31), 5q32 (3.14),
6q22 (2.48), 12q15 (2.86) and 19p13 (1.79).
Results
The HD Research Crossroads database and its
scoring schemes
At present, the HD Research Crossroads database con-
tains information about approximately 800 genes, for
which a direct or indirect relevance to HD pathophysi-
ology is indicated by available evidence. These genes
might therefore be considered as targets for the develop-
ment of therapies, which is a prime aim of HD research.
The target information is gathered by evaluation of pub-
lished studies and in-house screens.To obtain an overview of the current state of curation
by HD Crossroads, the distribution of TVS was visua-
lized (Figure 1). It is evident that the majority of genes
have a score of 3.0, which is assigned to a gene in the
case that a causal relationship with HD was shown
in vitro in cell culture or in vivo in a lower (non-rodent)
model. In contrast, a TVS larger than 3.0 requires evi-
dence from higher disease models or from linkage stud-
ies. Thus, it is not surprising that the number of genes
with high scores is considerably smaller. At present, only
SLC18A2 (VMAT2), a vesicular monoamine transporter,
has a TVS of 5.0. Its inhibition by tetrabenazine, the first
FDA-approved drug for treating HD-associated symp-
toms, results in decreased synaptic release of dopamine
[26]. Further high scoring genes (TVS= 4.5) are: GRIN1,
encoding a sub-unit of the glutamate receptor; and
CNTF, encoding the ciliary neurotrophic factor. The Htt
gene itself has a TVS of 4.0, as knock-down of its mu-
tant form by RNAi was neuroprotective in rodent mod-
els of HD [27].
For our analyses, we utilized the TVS to filter the list
of HD-relevant genes. We excluded genes with a TVS
lower than 3.0, since the current evidence for a causal
relationship of these genes with HD is limited. This step
resulted in a list of 532 genes, for which a causal
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with an updated TVS ≥ 3.0 were obtained directly from
the database curators. The total list of 694 HD-relevant
genes used for analyses and their corresponding TVS
can be found in the Additional file 1.
Functional composition of HD-relevant genes
For systematic evaluation of the filtered set of HD-
relevant genes, we utilized information from the GO
database. In GO, genes are annotated using a fixed vo-
cabulary for the description of (i) biological processes
(BP), in which a gene product is involved; (ii) molecular
functions (MF), which it executes; and (iii) cellular com-
partments (CC), in which it is located. The GO vocabu-
lary itself comprises more than 8 000 explicitly defined
terms and relations between them. For our purpose, we
utilized GO annotation for two tasks: firstly, we obtained
the overall composition of HD-relevant genes; and sec-
ondly, we calculated the statistical significance of en-
richment in HD-relevant genes for each GO category
(i.e. the number of HD-relevant genes included in a
GO category was compared with the number expected
by chance).
To facilitate interpretation of the functional compos-
ition, we restricted the number of GO BP categories. Ini-
tially, we only used terms in GO Slim, which comprises
127 categories, for main biological processes. Neverthe-
less, a direct interpretation was difficult due to the hier-
archical structure of GO categories. For example, when
a gene is ascribed to a category, it is automatically also
associated with all of the relevant parent categories.
Thus, a gene placed in the BP category “cell death” will
also be associated with the parent category “death”,
resulting in many dependent categories. To cope with
this data structure, we excluded categories, when the
majority of genes were associated with a single smaller
category. Additionally, we required that a minimum
number of 25 genes were included in a category. These
filtering steps reduced the number of biological pro-
cesses to 30. Figure 2A displays the distribution of HD-
relevant genes across the reduced set of BP categories.
Remarkably, a diverse set of processes was obtained;
with protein metabolism (38% of HD-relevant genes),
transport (28%), signal transduction (28%), catabolic
process (19%), and response to stress (18%) as the five
largest categories. Note that GO categories are not ex-
clusive, and genes or gene products can be associated
with multiple processes. The full list of BP categories, to-
gether with corresponding HD-relevant genes, can be
found in the supplementary materials (Additional file 2).
Although we reduced the list of GO categories, their
evaluation remained challenging, since they are not
mutually exclusive and genes can be associated with
multiple GO categories. In order to facilitate ourexamination and to obtain a more structured functional
profile, we carried out hierarchical clustering of GO BP
categories. The relative overlap in HD-relevant genes
was used as a similarity measure, so that categories shar-
ing HD-relevant genes tended to cluster. The dendro-
gram obtained (Figure 3) displays several larger clusters,
encapsulating processes related to homeostasis and cel-
lular response, transport and signaling, growth and dif-
ferentiation, as well as cell cycle and metabolism. Out of
these four cardinal groups, two (i.e. homeostasis and cel-
lular response, transport and signaling) can be tenta-
tively linked to excitotoxicity, which was one of the first
mechanisms proposed to explain the tissue-specific
damage in HD [28]. Excitotoxicity is a pathological
process, resulting in neuronal cell death caused by an
over-activation of glutamate receptors. It may contribute
to several neurodegenerative disorders, as well as other
brain injuries. N-Methyl-D-aspartic acid (NMDA) and
kainic acid (as well as glutamate itself at high levels) are
prime examples of excitotoxins, leading to an excessive
influx of calcium ions. A resulting failure of cellular cal-
cium homeostasis causes mitochondrial and membrane
damage, as well as the generation of free radicals and
might eventually trigger neuronal apoptosis.
Biological processes overrepresented among
HD-relevant genes
To evaluate the statistical significance of the observed
broad distribution, we subsequently performed an en-
richment analysis. Again, employing the full set of GO
categories, we found a strikingly large number of cat-
egories enriched in HD-relevant genes. In total, 212 cat-
egories with 25 or more HD-relevant genes yielded a
false discovery rate (FDR) of less than 0.01 for enrich-
ment (Additional file 2). Inspection of categories
enriched in HD-relevant genes identified processes that
are specific to the central nervous system such as
neuron development (26 genes; FDR= 7  10-4) and syn-
aptic transmission (40 genes; FDR= 6  10-9). However,
the majority of categories enriched in HD-relevant genes
were made up by generic cellular processes, many of
which have been previously linked to HD (Figure 2B).
For example, one of the most significantly enriched pro-
cesses is ubiquitin-dependent proteasome degradation
(50 genes; FDR=4 10-18). This reflects the substantial
evidence that the ubiquitin-proteasome system, which is
crucial for degrading and removing misfolded and
damaged proteins, becomes dysfunctional due to con-
gestion by mutant Htt [29-32]. Indeed, one of the main
hallmarks of HD neuropathology is the appearance of
intracellular ubiquitin-positive inclusion bodies of mu-
tant Htt [30]. Such anomalous protein aggregation might
be caused by an impaired ubiquitin-proteosome system,
as observed in the striatum and the cortex of human
AB
Figure 2 Distribution of HD-relevant genes across biological processes. A) Using GO annotation, HD-relevant genes were assigned to a
reduced set of GO Slim categories, representing biological processes. Only processes with more than 50 HD-relevant genes are displayed on the
pie-chart. Numbers refer to assigned HD-relevant genes. Biological processes that are significantly enriched (FDR≤ 0.01) are set in bold. Red labels
indicate an odds ratio≥ 2.0 with respect to the number of genes expected by chance. Note that the BP categories are not exclusive, i.e., a gene
can be assigned to several BP categories. B) Enrichment of HD-relevant genes displayed as odds ratios for selected biological processes from the
full list of GO categories (see Additional file 2).
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connected to pathogenesis of HD, include apoptosis (92
genes; FDR=5  10-12) [34-37], intracellular-vesicular
transport (71 genes; FDR= 2  10-10) [38-40] and cellular
ion homeostasis (30 genes; FDR= 8  10-4) [41,42].
Further examination of the results revealed highly sig-
nificant enrichment of a number of biological processes,for which the molecular details of their connection with
HD are not yet fully elucidated. For instance, RNA spli-
cing was highly enriched in HD-relevant genes (37
genes; FDR= 4  10-7). To explore the possible connec-
tion of RNA splicing to HD, we examined the experi-
mental evidence which supported the listing of
corresponding genes in HD Crossroads. We found that
Figure 3 Hierarchical clustering of biological processes. HD-relevant genes were assigned to biological processes. Similarity of biological
processes was defined by the percentage of shared genes. Based on the defined similarity, subsequent hierarchical clustering of biological
processes was carried out.
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gans and Drosophila cells were contributing the vast ma-
jority of genes (N = 33 genes) [13,43]. To determine
whether RNA splicing could also play a role in rodent
HD models and human patients, we re-analyzed several
publically available microarray data sets (Figure 4). Strik-
ingly, we found that genes related to RNA splicing tend
to be differentially expressed in human HD samples
compared with controls (p = 1  10-4), as well as in R6/2
mice compared with wild-type (p = 3  10-4). This sug-
gests a potential dysregulation of the splicing machinery
in HD. To explain the influence of RNA splicing genes
on aggregation, it has been proposed that the disruption
of RNA splicing interferes with protein homeostasis and
enhances aggregation by a general increase of misfolded
proteins [13]. Alternatively, RNA splicing might be dir-
ectly affected by distorted physical interaction with mu-
tant Htt. Here, work by Marcy MacDonald and
colleagues has provided some important cues [44,45].
First, they demonstrated that PRPF40A and PRPF40B,
human homologs of the yeast splicing factor pre-mRNA
processing protein 40, interact via WW domains with
the N-terminal proline-rich segment of Htt [44]. In a
follow-up study, PRPF40A was also found to be
recruited to inclusion bodies. More interestingly, both
pre-RNA splicing factors exhibited exaggerated binding
to mutant Htt [45]. Such aberrant interaction appears to
interfere with the efficiency of RNA splicing [46].
Intriguingly, another GO process highly enriched in
HD-relevant genes is the cell cycle (90 genes; FDR=3 
10-12). This is somewhat surprising, since the cell types
mainly affected by HD are differentiated neurons that
are typically seen as permanently post-mitotic. InFigure 4 Significance of enrichment in differentially expressed genes
the significance of enrichment in differentially expressed genes for GO pro
pathway. P-values were derived by Fisher’s exact test.contrast to the case for RNA splicing, the significance of
enrichment in this case is not due to a small number of
studies, but derives from integration of results from over
40 publications. We verified that the significance of the
cell cycle is not simply caused by a large overlap with
other distinct categories overrepresented among HD-
relevant genes. This was however not the case. GO
terms with large overlap were either cell-cycle related
such as “mitotic cell cycle” (64 genes) or rather of a gen-
eric nature such as “regulation of molecular function”
(47 genes) or “regulation of catalytic activity” (46 genes).
To obtain further support for a connection between HD
and the cell cycle, we again utilized genome-wide ex-
pression data. Remarkably, cell cycle genes tend to be
differentially expressed in human HD samples (p = 2 
10-4), HD mouse models (R6/2: p = 6  10-4; BDNF-KO:
p = 4  10-4), as well as a murine striatal cell line (p = 1 
10-4). Promoter analysis of HD-relevant genes also sup-
ported these observations. We detected a highly signifi-
cant enrichment in binding sites for the E2F
transcription factor family, which is crucial for cell cycle
control, upstream of HD-relevant genes (p < 10-15). It
should be noted, that results from expression data need
to be treated with caution. Except for the striatal cell
line, samples from human HD patients and mouse mod-
els can be expected to differ considerably in the compos-
ition of cell types from their corresponding controls,
since neurons are generally more vulnerable to mutant
Htt than glia cells. This might especially impact on the
expression of cell cycle genes, as glia cells are still mi-
totic. This difficulty in the interpretation of HD micro-
array data has been previously assessed in a study by
Hodges et al., in which laser-capture microdissectedfor human HD samples and disease models. The heat-map depicts
cess cell cycle and RNA splicing, as well as for the KEGG Wnt and ErbB
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data from homogenate samples for a small number of
brains [19]. In general, the expression changes observed
in both data sets displayed significant correlation. How-
ever, further study is warranted regarding this issue.
So far, studies connecting HD with the cell cycle
process are sparse. One notable connection was the
observed increase in cell proliferation and neurogenesis
in the adult human HD brain [47]. Examination of post-
mortem tissue showed that the degree of cell prolifera-
tion in the subependymal zone adjacent to the caudate
nucleus increased with pathological grade and length of
the Htt polyglutamine repeat. This finding was repro-
duced in mouse models of HD, although neurogenesis
might decrease in other parts of the brain during disease
progression [48-50]. An even more direct link between
the cell cycle and HD may be provided by the intriguing
possibility that re-entering the cell cycle leads to neuro-
degeneration and cell death of neurons. Although ma-
ture neurons are normally seen as post-mitotic, several
studies indicate that they ectopically re-express numer-
ous cell-cycle markers and replicate their DNA in vari-
ous neurodegenerative disorders, including Alzheimer’s
and Parkinson's disease [51]. These observations are in
line with experiments where blocking the cell cycle by
inhibiting cyclin-dependent kinases protects against
neuronal death [52,53]. To our knowledge, this potential
connection between cell cycle and neurodegeneration
has not been assessed yet for HD.
Cellular location of HD-relevant gene products
Next, we surveyed the cellular location of the products
of HD-relevant genes based on their GO Slim annota-
tion. We observed that they are widely distributed across
different compartments (Figure 5). The majority of HD-
relevant gene products are located in the cytoplasm
(63%), of which about a third are harbored in the cytosol
(i.e. the cytoplasm excluding organelles). Approximately
40% of gene products can be assigned to the nucleus
and a further 25% to the membrane part of the cell. The
statistical enrichment analysis yielded a high significance
for major cellular compartments: cytoplasm (438 genes;
FDR= 5  10-55), nucleus (276 genes; FDR= 4  10-10)
and membrane part (182 genes; FDR=2  10-4)
(Additional file 3). Additionally, the analysis also
revealed a significant enrichment in HD-relevant gene
products for organelles such as vesicles (52 genes; FDR=
8  10-8) and Golgi apparatus (45 genes; FDR= 0.05), as
well as molecular structures such as microtubules
(31 genes; FDR= 0.03) and ribosomes (31 genes;
FDR= 1  10-9). We also detected the spliceosomal com-
plex as highly enriched (33 genes; FDR= 3  10-16), which
is in concordance with the previously noted significance
of RNA splicing. In contrast, mitochondria did not reachsignificance (46 genes; FDR= 0.33), although mitochon-
drial alterations may play an important role in HD
pathogenesis. Notably, the mitochondrial envelope trea-
ted as a separate sub-compartment was detected as
enriched in HD-relevant gene products (26 genes; FDR=
0.02). This agrees with results of previous studies ex-
ploring mitochondrial changes due to mutant Htt in
both cell culture and animal models [54,55]. They
showed that N-terminal fragments of mutant Htt associ-
ate with the outer membrane of mitochondria and inter-
fere with trafficking of mitochondria, as well as with
mitochondrial membrane permeability; lowering the
threshold for calcium-induced release of cytochrome c.
In general, the distribution of HD-relevant genes
seems to reflect the widespread subcellular location of
the different products of Htt gene products: wild-type
Htt is primarily a cytoplasmic protein associated with a
variety of cellular structures and organelles such as
microtubules, vesicles, Golgi complex, endoplasmic
reticulum and axon terminals of neurons; whereas frag-
ments of mutant Htt can also be found in inclusion bod-
ies in the nucleus [56-58].Molecular functions of HD-relevant genes
We also evaluated the molecular functions of HD-relevant
genes based on their GO Slim annotations (Additional
files 4 and 5). The most common molecular functions of
HD-relevant genes were generic activities: protein binding
(73%; N=509 genes) and catalysis (42%; N=293 genes).
Both categories were also highly significant with
FDR= 5  10-45 and FDR = 3  10-14. More specific func-
tional categories overrepresented among HD-relevant
genes comprised transporters (70 genes; FDR=0.02),
structural molecules (54 genes; FDR=7  10-6) and protein
kinases (50 genes; FDR=3  10-5). In addition to GO anno-
tation, we employed information from the Pfam database
enabling the classification of HD-relevant genes into pro-
tein families (Additional file 6). The largest and most sig-
nificantly enriched Pfam family is protein kinase (41 genes;
FDR=10-6), which matches with the results from the GO
analysis. Although the database coverage by Pfam seems to
be lower than by GO, significance in enrichment was
obtained for various protein families with functions previ-
ously linked to HD. For example, we found that members
of the ligand-gated ion channel (5 genes; FDR=5  10-5), his-
tone deacetylase (6 genes; FDR=2  10-6), caspase (5 genes;
FDR=10-4) and ubiquitin (8 genes; FDR=10-4) family tend
to be HD-relevant. Notably, HD-relevant genes displayed
enrichment in several different families of chaperons:
Hsp20/alpha crystallin family (6 genes; FDR=3  10-7),
DnaJ domain family (10 genes; FDR = 10-4), Hsp70s (5
genes; FDR = 10-4), and TCP-1/cpn60 chaperonin family
(6 genes; FDR=10-4); which play important roles in
BA
Figure 5 Distribution of HD-relevant genes across cellular components. A) The pie-chart shows the distribution and the number of
HD-relevant gene products allocated to GO Slim categories for cellular components. GO terms that are significant (FDR≤ 0.01) are set in bold
and terms with an odds ratio≥ 2.0 are set in red. Note that the cellular component categories are not exclusive, i.e., a gene can be assigned to
several categories. B) The plot displays odd ratios for enrichment of selected cellular components.
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disassembly of macromolecular structures.
KEGG pathway analysis
Signaling pathways are of central importance for the
regulation and coordination of cellular events. Their ab-
errant activation is often linked to the development of
major diseases. Considerable research has been carried
out to identify components of cellular signaling, their se-
quential activation or deactivation, as well as their inter-
actions. Notably, numerous drugs have been established
to alter the function of relevant pathways. Although
their full complexity is still far from being completely
understood, signaling pathways – or rather the current
canonical models of them – can offer a conceptual
framework for the development of pharmacological
intervention.
To evaluate whether specific signaling pathways might
be implicated in HD or offer therapeutic targets, we uti-
lized the canonical models as defined in the KEGG path-
ways database. It is however important to keep in mind
that the pathway models are not exclusive, i.e., they
show considerable overlap, reflecting the frequently
observed synergy in signaling. Also, statistical signifi-
cance of enrichment in HD-relevant genes does not ne-
cessarily signify that the pathway plays a role in the
actual HD pathogenesis, but rather indicates that the
pathway can represent an effective target for
intervention.
Besides signaling pathways, KEGG comprises models
for a variety of processes and molecular complexes. The
mapping of the HD-relevant genes onto these models
revealed that processes such as apoptosis (21 genes;
FDR= 810-5), ubiquitin mediated proteolysis (23 genes;
FDR= 210-4) and endocytosis (22 genes; FDR= 0.08), as
well as protein complexes such as ribosome (31 genes;
FDR= 710-12), proteasome (21 genes; FDR= 710-10) and
gap junctions (16 genes; FDR= 110-4) tend to accumu-
late HD-relevant gene products (Additional file 7). We
observed that 13 signaling pathways were enriched
(FDR < 0.05). Figure 6 displays the distribution and odd
ratios of the major pathways with a minimum of 15 HD-
relevant genes included. The highest significance in en-
richment was obtained for MAPKK (42 genes; FDR=
210-4), neurotrophin (25 genes; FDR= 210-4), ErbB (18
genes; FDR= 110-3), and Wnt signaling (25 genes;
FDR= 210-3).
For several of these pathways, such as MAPK, mTOR,
insulin and calcium ion signaling, a role in HD had pre-
viously been proposed (see Table 1). Interestingly, we
also detected significant enrichment in a number of
pathways, which have received less attention for their
role in HD. For instance, Toll-like receptor (TLR) signal-
ing was found to be significantly enriched (17 genes;FDR= 10-3). Primarily known for their role in detecting
pathogens and activating the immune response, TLRs
have only recently been linked to neurodegeneration
[59]. In mouse models of Alzheimer disease, loss-of-
function mutation or knock-downs of TLRs were
reported to increase extra-cellular Aβ deposits, as well
as enhance cognitive deficits, which could be the result
of activated microglia [60,61]. In HD, where protein ag-
gregation produces intra-cellular inclusion bodies, a
more relevant process might be the activation of autop-
hagy by TLR via myeloid differentiation factor 88
(MyD88). Autophagy is a fundamental process that
degrades cystosolic constituents, including unfolded or
misfolded proteins and may have protective effects
against neurodegeneration by degrading toxic cytosolic
protein aggregates [62]. Thus, the link between TLR sig-
naling and autophagy could be a valuable site for thera-
peutic intervention in treating HD, but its relevance for
HD needs further evaluation, since TLRs are cell-type
specifically expressed and carry out a divergent range of
functions.
The importance of the Wnt pathway (which was
detected as enriched in HD-relevant genes) has been
well established for developmental processes. Its poten-
tial role in neurodegeneration, however, is less well char-
acterized [67]. In this context, previous research has
focused on the study of glycogen synthase kinase (GSK)-
3ß, which is a central component in the canonical Wnt
pathway and suppresses its activity unless stimulated by
the Wnt ligand. Notably, GSK-3ß is also an integral part
of other pathways such as insulin signaling and thus
emerges as a convergence point for different kinds of
signals [68]. In Alzheimer's disease, GSK-3ß has been
associated with hyperphosphorylation of tau protein and
the formation of neurofibrillary tangles - a hallmark of
Alzheimer's disease [67]. In addition to hyperphosphory-
lated tau, a decrease in nuclear ß-catenin (a transcrip-
tional co-activator whose turnover is regulated by GSK-
3ß phosphorylation) has been observed in transgenic
mice overexpressing GSK-3ß in hippocampal neurons
[69]. These changes were accompanied by increased
neuronal cell death and astrocytosis in the hippocampus.
Notably, blocking the activity of GSK-3 ß by lithium in
transgenic mice reduced aggregation of tau and axonal
degeneration [70]. For HD, several studies also point to
alterations in Wnt signaling. In a mouse HD model,
Gines et al. observed increased levels of activated Akt,
which could be reproduced in a derived striatial neur-
onal cell line [71]. This change was associated with in-
hibition of GSK-3ß phosphorylation and stabilization of
ß-catenin. The authors proposed that the activation of
Akt can be seen as an early pro-survival response to
enhanced NMDA receptor activity. Interestingly, an in-
crease in expression of cyclin D1, a target gene of the ß-
BA
Figure 6 Association with major KEGG pathways. A) KEGG signaling pathways with more than 15 HD-relevant genes and an odds ratio≥ 2.0
are included on the pie-chart. Numbers refer to HD-relevant genes in a pathway. Highly significantly enriched pathways (FDR≤ 0.01) are
highlighted by bold font. Pathways with odds ratio≥ 3.0 are set in red font. B) Odd ratios are displayed for enrichment of selected pathways.
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may be relevant for the previously indicated involvement
of cell cycle genes, as ectopic cyclin D1 expression was
also observed in sites of neuronal cell death in Alzhei-
mer's disease patients [72]. Consistent with earlier stud-
ies, direct blocking of GSK-3ß by lithium treatment in
the HD Drosophila model was protective against
polyglutamine-mediated toxicity [70]. The protection
was at least partially caused by the up-regulation of tran-
scriptional target genes in the Wnt pathway, since
reduced toxicity was observed for overexpression of
TCF. Thus, impairment of Wnt signaling seems to con-
tribute to neurodegeneration. In HD gene expressiondata, we found some indications for perturbation of the
canonical Wnt signaling in human patients (p = 0.02), R/
2 mice (p = 0.04) and in the HD striatal cell culture
model (p = 0.0001). In conclusion, it appears that an in-
volvement of Wnt signaling in neurodegeneration in
general, and specifically in HD, was indicated by differ-
ent lines of investigations. However, the molecular
details of this connection require further scrutiny, as an-
other recent study of the role of ß-catenin in HD indi-
cates. In agreement with the study by Gines et al.,
Humbert and co-workers have observed an accumula-
tion of ß-catenin in different HD models, as well
as post-mortem samples from patients [73]. The
Table 1 Signaling pathways with established links to HD
Pathway Evidence and suggested role in HD HD-relevant genes Significance (FDR)
Calcium ion signaling Mutant Htt affects calcium signaling in primary cultures
of medium spiny neurons from HD mouse models by
increasing the influx of extra-cellular Ca2+ and the
intra-cellular release of Ca2+ from ER [63,64]
25 0.01
MAPK signaling Induction of mutant Htt in PC12 cells leads to activation
of MAPK signaling via ERK and JNK. ERK
phosphorylation correlates with reduced apoptosis,
whereas JNK activity correlates with Htt-associated cell
death in a striatal HD cell line [65]
42 0.0002
Insulin signaling The insulin signaling pathway promotes survival of
striatal cells (transfected with mutant Htt) through
neuroprotective effects of Akt activation and triggers
autophagy mediated clearance of huntingtin via insulin
receptor substrate-2 in HD cell model [66]
20 0.02
mTOR signaling Inhibition of mTOR by rapamycin or by sequestration
into aggregates induces autophagy in HD cell model and
reduces neurodegeneration in HD fly and mouse model [62]
17 0.01
Signaling pathways that have been previously linked to HD progression and their corresponding significance of enrichment in HD-relevant genes.
Kalathur et al. BMC Neurology 2012, 12:47 Page 13 of 21
http://www.biomedcentral.com/1471-2377/12/47accumulation could be explained by an interference of
mutant Htt with the degradation of ß-catenin. Import-
antly, the accumulated ß-catenin was phosphorylated,
which normally predates ubiquitination and degradation
of ß-catenin, and did not result in transcriptional activa-
tion. In apparent contrast to previous studies, this accu-
mulation of ß-catenin appeared to be toxic, whereas its
enhanced degradation reduced polygluatamine-increased
neuronal toxicity.
Another pathway that was found to be significantly
enriched in HD-relevant genes in our study is ErbB sig-
naling. It is activated upon ligand binding to ErbB recep-
tor kinases, which are also known as epidermal growth
factor receptors (EGFRs). The pathway plays a key role
in mediating intercellular signals during organogenesis;
and aberrant expression of ErbB proteins and their
ligands have been associated with various types of can-
cers [74,75]. For neuronal development, neuregulins
(NRGs) as ligands of ErbBs are of importance. In par-
ticular, NRG1 and its receptor ErbB4 have been impli-
cated in neuronal migration, axon guidance and synapse
formation [76]. Notably, both proteins are expressed in
the adult brain and modulate the properties of glutama-
tergic synapses through the binding of ErbB4 to postsy-
naptic density protein 95 (PSD95). Interestingly, PSD95
itself can bind to both NMDA receptors and Htt. In
transfected cell lines, mutant Htt interferes with the abil-
ity of wild-type huntingtin to interact with PSD95 lead-
ing to the sensitization of NMDA receptors, thereby
potentially promoting excitotoxicity [77]. The polygluta-
mine expansion in Htt might also have a direct effect on
ErbB signaling and may antagonize the activation of
down-stream targets. Such a mechanism is supported by
the results of several studies. After demonstrating that
wild-type Htt is associated with the EGFR signalingcomplex after stimulation [78], Liu and co-workers
observed that EGF-stimulated phosphorylation of
MAPK, AKT and JNK is strongly reduced in cells trans-
fected with mutant Htt [79]. Their work also indicates
that mutant Htt interferes with the assembly of the sig-
naling complex associated with stimulated EGFR. These
findings agree well with results from in vivo studies in
flies [80]. Here, it was shown that co-expression of Htt
exon 1 with expanded polyglutamine tract strongly
inhibited EGFR-mediated MAPK phosphorylation in glia
cells. Notably, changes in expression of the glutamate
transporter could be reverted by activated MAPK, but
not activated EGFR alone, indicating that polyglutamine
acts on EGFR signaling upstream of MAPK. In our ana-
lysis, the genes associated with the ErbB signaling path-
way tend to be dysregulated in humans (p = 210-4) and
in the R6/2 mouse model (p =210-3). Finally, recent
studies have linked perturbations in ErbB signaling to
Alzheimer's disease, multiple sclerosis, and schizophre-
nia [81].
Prediction of genetic modifiers by data integration
strategy
Major efforts in HD research have been undertaken to
identify genetic modifiers, i.e., genes with polymorph-
isms that alter HD pathogenesis. A main strategy has
been genome-wide linkage analysis to detect genetic loci
modifying the age of disease onset. In general, the deter-
mination of genetic factors influencing complex traits
such as age of onset is notoriously difficult, as multiple
factors with incomplete penetrance are likely to play a
role. Despite considerable cost in resources, linkage ana-
lyses of pedigrees are a highly attractive paradigm, since
(by definition) the identified genetic modifiers have
demonstrated an effect in humans. In contrast, genome-
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available in lower organisms, but detected modifiers still
need to be validated for humans, presenting a major
bottleneck for the development of novel therapies. So
far, two genome-wide studies have been performed to
find loci influencing age of onset of HD [24,25,82]. Not-
ably, both studies detected multiple loci in distinct
population samples. A limitation of these studies, however,
is their coarse resolution, identifying rather long regions
with a large number of genes. Hence, finding genetic modi-
fiers remains challenging. The resolution can be expected
to improve with the use of microarray technologies for
genotyping, but this will also demand a considerably larger
number of samples in order to ensure sufficient statistical
power to detect associations [83].
We reasoned that the curated set of HD-relevant
genes could be of complementary value for the identifi-
cation of genetic modifiers. Since these genes have
demonstrated a causal relationship, mostly in lower HD
models, they are potential modifiers of HD, assuming the
underlying mechanisms are conserved. If their human
orthologs are additionally located in the regions linked to
altered age of onset, these genes can be regarded as prime
candidates for genetic modifiers of HD. Thus, we can nar-
row down the list of potential genetic modifiers found in
the linkage studies by employing information from HD
Crossroads.Figure 7 Chromosomal location of HD-relevant genes. Red marks high
been linked to the age of onset by genome-wide linkage studies. Blue marWith this objective, we first mapped all HD-relevant
genes to their loci on human chromosomes. The distribu-
tion across the human genome is displayed in Figure 7.
Subsequently, we searched for chromosomal regions, for
which potential linkage has been reported in both studies.
We found that peaks in the LOD score were reported for
locations in close vicinity in four distinct chromosomal
regions: i) 2q33-2q35 with LOD1 =1.63 at 2q33 by Li et al.
and LOD2=3.39 at 2q35 by Gáyan et al. ii) 4p16 with
LOD1= 1.93 and LOD2=1.49, iii) 5q31-32 with LOD1=
2.02 at 5q31-32 and LOD2 = 3.14 at 5q32 and iv) 6q22-24
with LOD1 = 2.28 at 6q23-24 and LOD2 = 2.48 at 6q22
[24,25]. Although some of these peaks may not have
reached genome-wide significance, the fact, that they were
detected in close proximity by two independent studies
supports the inclusion of the corresponding regions in our
analysis. In total, 26 HD-relevant genes can be found in
these loci. This reduces the total number of genes
(N= 1270) located in the indicated regions by a factor of
50. The list of the HD-relevant genes and their loci is
shown in Table 2. A complete listing of genes from HD-
Crossroads, which are located in any of the chromosomal
regions indicated by the genome-wide scans, can be found
in Additional file 8.
Two genes (i.e. MAP3K5/ASK1 and TCERG1) from
this list have already been proposed as genetic modifiers
in HD based on previous association studies [84,85].light HD-relevant genes located in chromosomal regions that have
ks represent HD-relevant genes outside these regions.
Table 2 Candidate list of genetic modifiers
Entrez ID Symbol TVS Chr. Band
Region= 2q33-2q35 7341 SUMO1 3 2 q33.1
9689 BZW1 3 2 q33.1
23451 SF3B1 3 2 q33.1
HD MAPS: LOD =1.63 (at 2q33) 1385 CREB1 3.5 2 q33.3
Gayan et al: LOD =3.39 (at 2q35) 7855 FZD5 3 2 q33.3
3300 DNAJB2 3 2 q35
8941 CDK5R2 3 2 q35
10109 ARPC2 3 2 q35
Region= 4p16 6286 S100P 3 4 p16.1
9948 WDR1 3 4 p16.1
HD MAPS: LOD =1.93 118 ADD1 3 4 p16.3
Gáyan et al : LOD =1.49 3064 HTT 4 4 p16.3
7469 WHSC2 3 4 p16.3
Region= 5q31-32 3308 HSPA4 3.5 5 q31.1
6500 SKP1 3 5 q31.1
2107 ETF1 3 5 q31.2
HD MAPS: LOD=2.02 (at 5q31-32) 3313 HSPA9 3 5 q31.2
Gáyan et al: LOD =3.14 (at 5q32) 7322 UBE2D2 3 5 q31.2
8841 HDAC3 4 5 q31.3
10915 TCERG1 3 5 q32
133522 PPARGC1B 3 5 q32
Region= 6q22-24 2444 FRK 3 6 q22.1
6206 RPS12 3 6 q23.2
HD MAPS: LOD =2.28 (at 6q23-24) 9439 MED23 3 6 q23.2
Gáyan et al: LOD =2.48 (at 6q22) 4217 MAP3K5 4 6 q23.3
2911 GRM1 3 6 q24.3
HD-relevant genes located in the four chromosomal regions implicated by both genome-wide scans [24,25]. The LOD scores reported in these studies for the
exact location are shown on the left column.
Kalathur et al. BMC Neurology 2012, 12:47 Page 15 of 21
http://www.biomedcentral.com/1471-2377/12/47Genetic variation around the loci of mammalian
mitogen-activated protein kinase kinase kinase 5
(MAP3K5), also termed apoptosis signal-regulating kin-
ase 1 (ASK1), has been associated with modified age of
onset [84]. ASK1 plays an important role in the poly-Q
induced neuronal cell death and is activated by various
stimuli. In particular, persistent ER stress and UPR acti-
vation triggered by extended polyQ repeats can activate
ASK1, inducing apoptosis [86]. Another previously pro-
posed modifier is the transcriptional activator CA150
(TCERG1) located at 5q32. It has been detected in
inclusion bodies and has been shown to interact with
full-length Htt in vitro [85]. TCERG1 contains a
gluatamine-alanine repeat in its N-terminus; its length
was negatively correlated with the age of onset [85,87].
Intriguingly, TCERG (besides its role as a transcriptional
co-activator) has also been associated with the spliceo-
some and exhibits a domain composition similar to the
Htt-interacting splicing factor PRPF40 (including bothWW and FF domains) [88]. Thus, TCERG1 may provide
a further connection between RNA splicing and HD. It
should be noted, however, that the identification of
these two potential genetic modifiers cannot serve to
cross-validate our approach (but rather to illustrate),
since the inclusion of at least one (MAP3K5) in HD
Crossroads was based on its association with age of
onset.
Among the other 24 genes identified, we were especially
interested in those that have high TVS in HD Crossroads
due to their potential as targets for novel therapies. The
compiled list included three genes with a TVS = 4, indicat-
ing that the phenotype in rodent HD models was improved
upon specific targeting of these genes. Besides ASK1 and
Htt, histone deacetylase 3 (HDAC3) has a TVS=4, since its
inhibition by small molecules yielded a positive effect in the
R6/2 mouse model [89]. A further two genes with TVS of
four were found in the set of genes with a chromosomal lo-
cation supported by only one study: cAMP-specific
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hibition of PDE4A showed ameliorated HD phenotype in
mice, where expression of neurotrophic factor NRTN was
shown to be protective for striatal neurons against excito-
toxicity induced by quinolinate injection [90,91].
The remaining HD-relevant genes in the selected
regions are involved in wide range of processes, of
which, some play important roles in HD. For instance,
metabotropic glutamate receptor 1 (GRM1), a G-
protein-coupled receptor with its gene located at 6q24,
is a component of the glutamatergic neurotransmission
apparatus and thus might be linked to excitotoxicity. Al-
though the over-stimulation by glutamate is mainly
inflicted through ionotropic NMDA receptors, studies
have indicated that GRM1 modulates glutamatergic
neurotransmission and eventually excitotoxicity [92]. In-
hibition of GRM5, which belongs to the same sub-group
of metabotropic glutamate receptors as GRM1, has
already been demonstrated to attenuate disease progres-
sion in an HD mouse model [93]. Moreover, other genes
involved in glutamatergic neurotransmission have previ-
ously been proposed to act as genetic modifiers of HD:
GRIK2 encoding the kainite-type glutamate receptor; as
well as GRIN2A and GRIN2B, encoding NMDA recep-
tor sub-units [87].
Another gene which can readily be linked to a poten-
tially disease-relevant mechanism is PPARGC1B. It acti-
vates various transcription factors and nuclear receptors
such as the estrogen receptor alpha and is involved in
the regulation of energy metabolism, which appears to
be affected in HD. Remarkably, a recent study associated
another member of the same gene family (i.e.,
PPARGC1A) with a delay in age of onset of motor
symptoms in HD patients [94].
A gene which may also warrant closer inspection is
CDK5R2, which encodes a neuron-specific activator
(p39) of Cyclin-dependent kinase-5 (CDK5). In con-
trast to other cyclin-dependent kinases, CDK5 appears
not to be directly involved in regulating progression
through the cell cycle, but has been associated with
neurogenesis, as well as with neurodegenerative dis-
ease [95,96]. Its localized activity in neurons can be
attributed to its activators (p35 and p39). Interest-
ingly, CDK5 is a proline-directed serine/threonine kin-
ase with numerous substrates, one of which is Htt. It
could be shown that phosphorylation of mutant Htt
by CDK5 reduces its cleavage by caspases, as well as
its toxicity [97].
As this brief review of the derived gene list suggests,
an integrative strategy can deliver promising candidates
for genetic modifiers associated with various disease-
related mechanisms. We anticipate that this approach
will also help to accelerate identification of candidate
genes in ongoing genome-wide association studies.Discussion
Two of the most puzzling features of HD have been the
variability in its clinical manifestation, as well as the
complexity of underlying molecular changes; both are in
apparent contradiction to the known monogenic nature
of the disease. Light has been collectively shed on this
paradox by many studies, revealing a strikingly large
number of genes associated with molecular pathogenesis
of HD. As it is becoming clear, progression of HD –
although caused by the mutation of a single gene – is
likely to be influenced by a plethora of genes with dis-
tinct functions. Moreover, studies linking genes - other
than Htt - to the pathogenesis have certainly given us a
better understanding of HD and have presented cues to
develop novel therapies. At the same time, however, the
sheer number of HD-relevant genes argues that a focus
beyond studying genes as independent entities is needed
and that it will be crucial to obtain a consolidated over-
view of the biological processes and pathways that are
affected by HD.
In this study, we report the functional composition of
a large set of known HD-relevant genes and thereby pro-
vide a first step towards a comprehensive view of the
complex molecular landscape of HD. The basis of our
work has been a curated set of 694 genes, which have
been either directly or indirectly associated with HD in
the HD Research Crossroads database. The composition
of this set of genes was analyzed with respect to its asso-
ciation with molecular mechanisms. To detect processes
involved in HD pathophysiology, we performed various
GO and pathway analyses. Enrichment analyses enabled
us to pinpoint processes overrepresented among HD-
relevant genes.
Clearly, it has to be acknowledged that statistical sig-
nificance is only an initial indicator for biological signifi-
cance and our results need to be carefully interpreted.
Statistical significance might be exaggerated by potential
selection biases in HD research. Equally, processes can
be pivotal for HD pathogenesis without being statisti-
cally enriched in HD-relevant genes. Also, since GO cat-
egories and KEGG pathways are not exclusive, and can
have considerable overlap, significance of one category
or pathway might therefore be influenced by the signifi-
cance of other categories and pathways. This may lead
to an overestimated significance. An example from the
list of KEGG pathways illustrates this well. The pathway
“Epithelial cell signaling in Helicobacter pylori infection”,
which appears unrelated to HD pathogenesis, was never-
theless significantly enriched in HD-relevant genes due
to inclusion of several members of the MAPK pathway.
Furthermore, the results of our analysis could also be
influenced by general biases underlying the examination
of genes in HD research, as well as their curation in HD
Crossroads. One potential bias in HD Crossroads could
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gets, which could influence the enrichment analysis for
molecular function of HD-relevant genes. This may be
the case for several functions (such as kinase activity),
since they also can be enriched among drug targets (see
supplementary analysis in Additional file 5).
Despite these limitations, we observed that our statis-
tical analyses are in good concordance with previous
studies, which were based on the study of single or a
small subset of genes. For instance, we could recover the
association of protein degradation, cytotoxicity, stress re-
sponse and metabolism, as well as pathways such as cal-
cium, neurotrophin and mTOR signaling with HD. Basic
molecular functions such as protein binding, RNA bind-
ing and enzyme activities (by protein kinases, peptidases,
catalases and hydrolases) are also enriched. Examining
their association with cellular components shows that
HD-relevant proteins are predominantly located in the
cytoplasm.
More interestingly, evaluation of HD-relevant genes
pointed to several processes and pathways whose con-
nections to HD have received less attention so far. For
example, cell cycle and pathways such as Wnt and ErbB
signaling were shown to be strongly enriched in HD-
relevant genes. Our analyses suggest that these processes
and pathways should be considered for further inspec-
tion and might be novel targets for therapeutic interven-
tion for HD. Importantly, the significance of the cell
cycle, as well as TLR, Wnt and ErbB pathways was not
due to a single study included in the HD Crossroads. In
fact, the 25 HD-relevant genes in the Wnt pathway were
derived from evaluation of 20 studies. Similarly, the 18
HD-relevant genes in the ErbB pathway and the 17
genes in the TLR pathway stem from 15 and 13 distinct
publications, respectively. Thus, the detected signifi-
cance in enrichment can be seen as a genuine result of
the integration of numerous individual studies demon-
strating the value of HD Crossroads.
For our analysis, we used a filtered set of genes from
HD Crossroads. We only included genes for which a
causal relationship had been observed in a HD model or
was indicated in an association or linkage study. How-
ever, it can be the case that genes with lower target
validation scores in HD Crossroads might point to
disease-relevant mechanisms of greater novelty. We
have, therefore, additionally performed enrichment ana-
lyses for GO categories, KEGG pathways and Pfam fam-
ilies, as well as mapping to chromosomal locations for
the full list of genes included in HD Crossroads. In gen-
eral, the majority of enriched categories, pathways and
protein families were detected as significant, irrespective
of the filter for the TVS, as a comparison of the two
databases has shown (Additional file 5). For the full list of
genes from HD Crossroads, a larger number of significantcategories, pathways and protein families were detected.
This was mainly due to the fact, that they surpassed the
applied threshold for a minimum number of genes (e.g.,
25 for GO categories). Notably, several additional GO cat-
egories, KEGG pathways and Pfam families with apparent
relevance were found. For example, the KEGG pathway
“Neuroactive ligand-receptor interaction” was detected as
significantly enriched, as well as the Pfam Sir 2 family,
when the full HD Crossroads gene list was analyzed. Thus,
the additional results might provide valuable pointers to
mechanisms for further inspection and are included in the
corresponding Additional files 2, 3, 4, 6, 7 and 8. It should
be noted, however, that the evidence for genes with low
TVS is often indirect, and thus should be treated with
caution.
Remarkably, the complex nature of HD pathophysi-
ology was highlighted by the results of our analysis. The
large number of significantly enriched processes might
be somewhat surprising, but it could be a direct conse-
quence of the multi-functional role of Htt as a scaffold
protein [10]. Moreover, the performed bioinformatic
analyses, although extensive, have limited power to clar-
ify causal relationships. Many detected processes might
not be directly affected by mutant Htt, but may be acti-
vated as secondary responses. Accumulation of toxic
mutant Htt eventually generates general stress, which
leads to a wide activation of cellular response mechan-
isms. Due to the late disease onset and the difficulty in
monitoring pre-symptomatic changes, the distinction of
primary and secondary responses will remain difficult
for HD, as is generally the case for late-onset neurode-
generative diseases. To distinguish cause and effect, the
incorporation of time-series data will be crucial for an
improved understanding of the molecular mechanisms
and, finally, for dissection of the temporal order of dis-
ease progression.
In addition to the examination of the functional com-
position of HD-relevant genes, existing knowledge (as
presented by curated causal relationships in HD Cross-
roads) was combined with results from linkage studies
to create a list of candidates of genetic modifiers. The
approach resulted in 26 HD-relevant genes located in
the regions that were previously linked to age of onset.
Some of these genes have high TVS, representing prime
candidates for further investigation. Notably, this ap-
proach reduces the number of possible genetic modifiers
by a factor of 50 and can thus greatly assist in the
prioritization of targets.
Conclusions
The results of our analyses reflect many discoveries that
elucidated molecular mechanisms in HD. More remark-
ably, they also strongly support a functional relevance of
processes, that have received little attention, or that have
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discussed several such processes and pathways, but
many others that showed statistical significance still war-
rant review. To this end, we have provided extensive
supplementary material, including the full lists of bio-
logical processes and molecular pathways associated
with HD through statistical analyses and gene annota-
tion. Researchers are encouraged to consult the supple-
mentary information as a resource to help define the
role of different molecular processes in HD and utilize
the relevant set of HD-relevant genes for further ana-
lyses. Here, it might be useful to integrate additional
types of data. In our present study, we utilized gene ex-
pression to assess whether selected processes and path-
ways show dys-regulation in HD. We did not use
expression data to assess single genes. Such an inte-
grated approach could prove to be beneficial for further
consolidation of HD-relevant genes in future studies.
Similarly, the integration of chromosomal location might
help to pinpoint candidate modifiers, especially if higher
resolution data becomes available.
As the relevance of many genes for HD is still un-
known, our analysis presents only a snapshot of current
knowledge; ongoing research will give us a more
complete picture. Nevertheless, our analysis can be seen
as a first step towards a comprehensive list of biological
processes, molecular functions and pathways associated
with HD and may provide a basis for constructing more
holistic disease models. Furthermore, the results pre-
sented can serve as an entry point for researchers new
to HD research. We hope that our work can help to bet-
ter understand the complexity of HD and contribute to
the identification of potential drug targets.Additional files
Additional file 1: HD-relevant genes. Excel file with the list of 694 HD-
relevant genes used for analyses and their corresponding TVS and the list
of genes as downloaded from HD Crossroads. Note that the first gene list
also includes genes provided directly from the HD Crossroads curators,
which are not included in the downloaded gene list.
Additional file 2: Enriched biological processes. Excel file with three
tables of biological processes and their statistical significance. A) Table
with biological processes enriched in the filtered set of HD-relevant
genes with FDR < 0.25. B) Table with reduced set of biological processes
as defined by the GO Slim and used for figure 4. C) Table of biological
processes enriched among the full set of genes curated in HD
Crossroads. All tables include the GO ID of the biological process,
unadjusted p-value, FDR, odds ratio, expected gene count, observed
count, total number of genes associated with the biological process, as
well as the gene symbols of HD-relevant genes within the GO category.
To be included in table A, B or C, a minimum of 25 genes was required.
Additional file 3: Enriched cellular components. Excel file with tables
of cellular component categories enriched in: (A) filtered set of
HD-relevant genes; and (B) the full set of genes curated in HD
Crossroads. Statistical significance is given for each category. Format and
filtering criteria are the same as for table S2A.Additional file 4: Enriched molecular functions. Excel file with tables
of molecular function categories enriched in: (A) filtered set of HD-
relevant genes; and (B) the full set of genes curated in HD Crossroads;
statistical significance is given for each category. Format and filtering
criteria are the same as for table S2A.
Additional file 5: Supplementary analyses and figures. PDF
document describing supplementary analyses and including
supplementary figures S1, S2, S3, and S4.
Additional file 6: Enriched Pfam protein families. Excel file with
tables of Pfam protein families enriched in: (A) filtered set of HD-relevant
genes; and (B) the full set of genes curated in HD Crossroads; statistical
significance is given for each family. The format is the same as for table
S2A, however only a minimum number of 5 genes was required.
Additional file 7: Enriched KEGG pathways. Excel file with tables of
KEGG pathways enriched in: (A) filtered set of HD-relevant genes; and (B)
the full set of genes curated in HD Crossroads; statistical significance is
given for each pathway. The format is the same as for table S2A,
however only a minimum number of 10 genes was required.
Additional file 8: List of HD-relevant genes located in chromosomal
loci, for which suggestive linkage with age of onset has been
reported. Excel file with table of HD-relevant genes located in
chromosomal regions, for which suggested evidence for linkage has
previously been found in two independent studies [24,25]. The table lists
the TVS and chromosomal location for each gene.
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